Anergis

Anergis starts phase II trial with birch pollen allergy vaccine AllerT

Monday, December 15, 2014

Anergis, a Swiss-based company developing proprietary ultra-fast allergy vaccines, has begun a phase II trial designed to finalize the dose selection for the phase III study of AllerT. AllerT is Anergis´ lead vaccine against birch pollen allergy that originated from the company´s proprietary Contiguous Overlapping Peptide (COP) platform. COPs are pharmaceutical-grade, long-peptide immunotherapeutics designed for an ultra-fast, safe and long-lasting treatment of allergy patients.

[Read More]